Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026
Pulmovant, the Roivant (Nasdaq: ROIV) subsidiary focused on pulmonary disease, said topline results from the Phase 2 PHocus study of mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented at the ERS International Congress 2026 at 6:15 a.m. ET on Tuesday, September 8, 2026. PHocus was a randomized, double-blind, placebo-controlled global trial that enrolled 135 adults with PH-ILD to assess the safety and efficacy of mosliciguat, a potential first-in-class, once-daily, inhaled sGC activator.
Key figures
- Drug Name
- mosliciguat
- Phase Of Trial
- Phase 2
- Trial design
- randomized, double-blind, placebo-controlled
- Trial enrollment
- 135
- Presentation time
- 2026-09-08 6:15 a.m. ET (12:15 CEST)
- Phase1b pvr reduction
- up to 38%
- Ph ild patient population us europe
- up to 200,000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.